Nicolas Azzopardi

Présentation

Publications

Article dans une revue (28)

Mixed genetic background better recapitulates developmental and psychiatric phenotypes and heterogeneity than inbred C57BL/6J mice Ana Dudas,Ana Novak,Caroline Gora,Emmanuel Pecnard,Nicolas Azzopardiet al. Scientific Reports, 2025, ⟨10.1038/s41598-025-26215-6⟩ Article dans une revue hal-05182452v2
Effect of the social environment on olfaction and social skills in wild-type and a mouse model of autism Caroline Gora,Ana Dudas,Lucas Court,Anil Annamneedi,Gaëlle Lefortet al. Translational Psychiatry, 2024, 14 (1), pp.464. ⟨10.1038/s41398-024-03174-6⟩ Article dans une revue hal-04785377v1
Relationship between cetuximab target-mediated pharmacokinetics and progression-free survival in metastatic colorectal cancer patients Sarah Lobet,Gilles Paintaud,Nicolas Azzopardi,Christophe Passot,Morgane Cauletet al. Clinical Pharmacokinetics, 2023, 62 (9), pp.1263-1274. ⟨10.1007/s40262-023-01270-2⟩ Article dans une revue hal-04285346v1
Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial Sophie Dupuis-Girod,Sophie Rivière,Christian Lavigne,Anne-Emmanuelle Fargeton,Brigitte Gilbert-Dussardieret al. Journal of Internal Medicine, 2023, 294 (6), pp.761-774. ⟨10.1111/joim.13714⟩ Article dans une revue hal-04285361v1
Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX) David Tougeron,Sheik Emambux,Laure Favot,Thierry Lecomte,Ewa Wierzbicka-Hainautet al. OncoImmunology, 2020, 9 (1), pp.1848058. ⟨10.1080/2162402X.2020.1848058⟩ Article dans une revue hal-03149030v1
CD4+ count‐dependent concentration‐effect relationship of rituximab in rheumatoid arthritis Amina Bensalem,Denis Mulleman,Gilles Thibault,Nicolas Azzopardi,Philippe Goupilleet al. British Journal of Clinical Pharmacology, 2019, ⟨10.1111/bcp.14102⟩ Article dans une revue hal-02376303v1
Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited Amina Bensalem,Denis Mulleman,Gilles Paintaud,Nicolas Azzopardi,Valerie Gouilleux-Gruartet al. Clinical Pharmacokinetics, 2019, ⟨10.1007/s40262-019-00826-5⟩ Article dans une revue hal-02316414v1
In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration Thomas Secher,Emilie Dalonneau,Marion Ferreira,Christelle Parent,Nicolas Azzopardiet al. Journal of Controlled Release, 2019, 303, pp.24-33. ⟨10.1016/j.jconrel.2019.04.005⟩ Article dans une revue hal-02179896v1
Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans David Ternant,Nicolas Azzopardi,William Raoul,Theodora Bejan-Angoulvant,Gilles Paintaud Clinical Pharmacokinetics, In press, ⟨10.1007/s40262-018-0680-3⟩ Article dans une revue hal-01821717v1
Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group Mira Tout,Anne-Laure Gagez,Stéphane Lepretre,Valérie Gouilleux-Gruart,Nicolas Azzopardiet al. Clinical Pharmacokinetics, 2017, 56 (6), pp.635 - 647. ⟨10.1007/s40262-016-0470-8⟩ Article dans une revue hal-01769807v1
Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti–TNF-α Antibodies after a Single Injection in Mice Christophe Arnoult,Guillaume Brachet,Diana Cadena Castaneda,Nicolas Azzopardi,Christophe Passotet al. Journal of Immunology, 2017, 199 (2), pp.418-424. ⟨10.4049/jimmunol.1601246⟩ Article dans une revue hal-02019721v1
Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients Morgane Caulet,Thierry Lecomte,Olivier Bouché,Jérôme Rollin,Valérie Gouilleux-Gruartet al. Clinical Pharmacokinetics, 2016, 55 (11), pp.1381 - 1394. ⟨10.1007/s40262-016-0406-3⟩ Article dans une revue hal-01769811v1
Cetuximab pharmacokinetics influences overall survival in head and neck cancer patients Yoann Pointreau,Nicolas Azzopardi,David Ternant,Gilles Calais,Gilles Paintaud Therapeutic Drug Monitoring, 2016, 38 (5), pp.567-72. ⟨10.1097/FTD.0000000000000321⟩ Article dans une revue hal-01769813v1
Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab Jérôme Rollin,Audrey Payancé,Valérie Gouilleux-Gruart,Michelle Boisdron-Celle,Nicolas Azzopardiet al. Pharmacogenomics, 2015, 16 (18), pp.2035-2043. ⟨10.2217/pgs.15.139⟩ Article dans une revue hal-02381189v1
Pharmacokinetics of adalimumab in Crohn’s disease David Ternant,Konstantinos Karmiris,Séverine Vermeire,Celine Desvignes,Nicolas Azzopardiet al. European Journal of Clinical Pharmacology, 2015, 71 (9), pp.1155-1157. ⟨10.1007/s00228-015-1892-1⟩ Article dans une revue hal-01769822v1
Dose – response relationship of bevacizumab in hereditary hemorrhagic telangiectasia Nicolas Azzopardi,Sophie Dupuis-Girod,David Ternant,Anne-Emmanuelle Fargeton,Isabelle Ginonet al. mAbs, 2015, 7 (3), pp.630 - 637. ⟨10.1080/19420862.2015.1022693⟩ Article dans une revue hal-01769884v1
Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system Laurent Guilleminault,Nicolas Azzopardi,Christophe Arnoult,Julien Sobilo,Virginie Hervéet al. Journal of Controlled Release, 2014, 196, pp.344-354. ⟨10.1016/j.jconrel.2014.10.003⟩ Article dans une revue hal-02376374v1
VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations Virginie Herve,Nathalie Rabbe,Laurent Guilleminault,Flora Paul,Laurène Schlicket al. mAbs, 2014, 6 (6), pp.1638 - 1648. ⟨10.4161/mabs.34454⟩ Article dans une revue hal-01769888v1
Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies Christophe Passot,Nicolas Azzopardi,Sylvaine Renault,Nadine Baroukh,Christophe Arnoultet al. mAbs, 2014, 5 (4), pp.614 - 619. ⟨10.4161/mabs.24815⟩ Article dans une revue hal-01769897v1
Influence of plasma exchange on rituximab pharmacokinetics Nicolas Azzopardi,Maud François,Emeline Laurent,Gilles Paintaud,Béatrice Birmelé British Journal of Clinical Pharmacology, 2013, 76 (3), pp.486 - 488. ⟨10.1111/bcp.12167⟩ Article dans une revue hal-01769901v1
Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients Nicolas Azzopardi,Thierry Lecomte,David Ternant,Michelle Boisdron-Celle,Friedrich Pilleret al. Clinical Cancer Research, 2011, 17 (19), pp.6329 - 6337. ⟨10.1158/1078-0432.CCR-11-1081⟩ Article dans une revue hal-01769933v1
Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients Nicolas Azzopardi,Therry Lecomte,David Ternant,Michele Boisdron-Celle,Friedrich Pilleret al. Fundamental & Clinical Pharmacology, 2011, 25, pp.34-34 Article dans une revue hal-00616314v1
The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors Agnes Maillet,Laurent Guilleminault,Etienne Lemarié,Stephanie Lerondel,Nicolas Azzopardiet al. Pharmaceutical Research, 2011, 28 (9), pp.2147 - 2156. ⟨10.1007/s11095-011-0442-5⟩ Article dans une revue istex hal-01769936v1
Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis D. Chu Miow Lin,D. Mulleman,N. Azzopardi,I. Griffoul-Espitalier,J.-P. Valatet al. Scandinavian Journal of Rheumatology, 2010, 39 (1), pp.97-98 Article dans une revue hal-00616813v1
Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis D Chu Miow Lin,D. Mulleman,N. Azzopardi,G Griffoul-Espitalier,P Valatet al. Scandinavian Journal of Rheumatology, 2010, 39 (1), pp.97 - 98. ⟨10.3109/03009740903177745⟩ Article dans une revue hal-01769938v1
An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Cetuximab Nicolas Ceze,David Ternant,Friedrich Piller,Danielle Degenne,Nicolas Azzopardiet al. Therapeutic Drug Monitoring, 2009, 31 (5), pp.597-601 Article dans une revue hal-00521871v1
Aerosoltherapy for lung tumors using the monoclonal antibody cetuximab Agnes Maillet,Laurent Guilleminault,Nicolas Azzopardi,Jerome Montharu,Laurent Vecellioet al. Journal of Thoracic Oncology, 2009, 4 (9), pp.S600-S600 Article dans une revue hal-00616858v1
Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis Juliette Thariat,Nicolas Azzopardi,Frederic Peyrade,Vincent Launay-Vacher,Jose Santiniet al. Journal of Clinical Oncology, 2008, 26 (25), pp.4223-4225 Article dans une revue hal-00616934v1

Poster de conférence (1)

Relationship between rituximab concentration and autoantibody levels in anti-neutrophil cytoplasmic antibody associated vasculitis A Bensalem,D Ternant,N. Azzopardi,G. Paintaud,V Gouilleux-Gruartet al. EULAR 2019, Jun 2019, MADRID, Spain Poster de conférence hal-02149477v1

Pré-publication, Document de travail (3)

The insertion of Neomycin cassette impairs maternal and social behaviors in Arc/Arg3.1 knock-out mice Ana Dudas,Emilia Caire,Abdurahman Hassan a Kuku,Nicolas Azzopardi,Anil Annamneediet al. 2025 Pré-publication, Document de travail hal-05056624v1
Hormone-regulated dynamics of mRNA distribution on ribosomes in Sertoli cells Xavier Leray,Julia Morales,Aurélie Tréfier,Kelly León,Thomas Bourquardet al. 2025 Pré-publication, Document de travail hal-04869030v1
Effect of the social environment on olfaction and social skills in WT and mouse model of autism Caroline Gora,Ana Dudas,Lucas Court,Anil Annamneedi,Gaëlle Lefortet al. 2023 Pré-publication, Document de travail hal-04312827v1